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Detailed description of diagnostic adjudication  
 
 
All patients with hs-cTnI concentrations above the sex-specific 99th percentile were classified 
according to the Third Universal Definition of Myocardial Infarction in use at the time of the 
trial. In this pre-specified secondary analysis, we updated this classification in accordance with 
the Fourth Universal Definition of Myocardial Infarction. The final diagnosis was adjudicated 
according to a pre-specified list (cardiac diagnoses: acute aortic dissection, acute heart failure, 
cardiomyopathy, chronic heart failure, hypertensive heart disease, myopericarditis, non-ST 
segment elevation myocardial infarction, ST-segment elevation myocardial infarction, recent 
myocardial infarction, tachyarrhythmia, Takotsubo cardiomyopathy or valvular heart disease; 
non-cardiac diagnoses: acute kidney injury, chronic kidney disease, chronic obstructive 
pulmonary disease, gastrointestinal bleed, pulmonary embolism, sepsis, or other). Two 
physicians independently reviewed all clinical information, blinded to study phase, with 
discordant diagnoses resolved by a third reviewer. Clinical information included the dates and 
times of presentation and final discharge, the initial emergency department assessment and 
final discharge letter as documented in the electronic care record, with summaries of all 
investigations undertaken during the index presentation including the electrocardiogram. The 
adjudication panel had access to raw clinical information including haemoglobin, creatinine 
and high-sensitivity cardiac troponin I concentrations, and the reports from invasive coronary 
angiography. Type 1 myocardial infarction was defined as myocardial necrosis (any hs-cTnI 
concentration above the 99th percentile with a rise and/or fall in hs-cTnI concentration where 
serial testing was performed) in the context of a presentation with suspected acute coronary 
syndrome with symptoms or signs of myocardial ischemia on the electrocardiogram. Patients 
with symptoms or signs of myocardial ischemia and evidence of increased oxygen demand or 
decreased supply (for example, tachyarrhythmia, hypotension, or anaemia) secondary to an 
alternative pathology and myocardial necrosis were defined as type 2 myocardial infarction. 
The classification of type 2 myocardial infarction also includes patients with coronary 
vasospasm, embolism or spontaneous dissection without evidence of atherothrombosis related 
to coronary artery disease. Type 4a myocardial infarction was defined in patients with 
symptoms or signs of myocardial ischemia following percutaneous coronary intervention 
where hs-cTnI concentrations were 5-fold greater than the 99th percentile, or increased further 
if elevated prior to the procedure. Type 4b myocardial infarction was defined where myocardial 
ischemia and myocardial necrosis were associated with stent thrombosis documented at 
angiography. Myocardial injury was defined if hs-cTnI concentrations were above the 99th 
percentile in the absence of any clinical features of myocardial ischemia. All non-ischemic 
myocardial injury was classified as acute, unless a change of <20% was observed on serial 
testing or the final adjudicated diagnosis was chronic heart failure or chronic renal failure, 






Table I. Baseline characteristics of patients stratified by primary presenting complain of chest pain or other symptoms  
 
  Overall Primary presentation 
with chest pain  
Other primary  
symptom  
No. of participants 46,092 33,319 7,525 
Age(years) 61.0 (49.0 - 75.0) 58.0 (47.0 - 72.0)  71.0 (58.0 - 81.0) 
Sex (Male) 24,433 (53.0) 17,967 (53.9) 3,837 (51.0) 
Adjudicated diagnosis     
Type 1 myocardial infarction 33,319 (81.6) 3,315 (10.0) 377 (5.0) 
Type 2 myocardial infarction 1,977 (4.8) 744 (2.2) 282 (4.7) 
Acute myocardial injury 2,003 (4.9) 569 (1.7) 926 (12.3) 
Chronic myocardial injury 1,213 (3.0) 559 (1.7) 572 (7.6) 
No myocardial injury 2,332 (5.7) 28,080 (84.3) 5,361 (71.3) 
Past medical history     
Coronary artery disease 11,349 (24.6) 8,046 (24.2) 1,824 (24.2) 
Myocardial infarction 4,003 (8.7) 2,818 (8.5) 623 (8.3) 
Diabetes mellitus 3,274 (7.1) 2,283 (6.9) 587 (7.8) 
Cerebrovascular disease 2,732 (5.9) 1,709 (5.1) 667 (8.9) 
Hypercholesterolaemia 18,412 (39.9) 12,641 (38.0) 3,521 (46.8) 
Heart failure 3,908 (8.5) 2,377 (7.1) 1,035 (13.8) 
Abnormal renal function 8,398 (18.7) 4,869 (15.0) 2,456 (33.4) 
Previous revascularisation     
PCI 3,543 (7.7) 2,686 (8.1) 456 (6.1) 
CABG 747 (1.6) 511 (1.5) 149 (2.0) 
Electrocardiogram*     
Normal 2,522 (37.3) 1,844 (40.6) 458 (27.4) 
Myocardial ischemia 1,740 (25.7) 1,277 (28.1) 369 (22.1) 
ST depression 1,185 (17.5) 858 (18.9) 248 (14.8) 
ST elevation 243 (3.6) 179 (3.9) 56 (3.4) 
 
 5 
T-wave inversion 1,191 (17.6) 831 (18.3) 272 (16.3) 
Observations, haematology, and 
clinical chemistry  
 
  
Systolic blood pressure, mmHg 139.4 (28.9) 140.5 (27.8) 136 (31.9) 
Heart rate, bpm 85.9 (26.4) 82.7 (24.2) 94 (30.4) 
Haemoglobin, g/L 137.2 (18.2) 138.0 (17.5) 134.6 (19.9) 
Presented as No. (%), mean±SD or median [25th percentile – 75th percentile]. Abbreviations: CABG = coronary artery 
bypass grafting; PCI = percutaneous coronary intervention. *Electrocardiographic data reported for the 15% 
(6,218/40,829) of patients with myocardial infarction or myocardial injury who had electrocardiographic and symptom 











46,092 eligible for 
inclusion in primary 
analysis
Excluded:
ST-elevation myocardial infarction n= 925
Unable to adjudicate diagnosis n= 1,241
No troponin result available n= 24
Adjudicated diagnosis
Symptoms at presentation:
















Serial sampling within 




Type 1 myocardial infarction n= 2,451
Type 2 myocardial infarction n= 594
Acute myocardial injury n= 437
Chronic myocardial injury n= 674
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Figure I. Flow-Chart of the Study and Analysis Population 
 
Figure II. Discrimination of High-Sensitivity Cardiac Troponin I at Presentation for Type 1 Myocardial Infarction With and Without 
an Absolute and Relative Change in Cardiac Troponin Concentration 
 
Comparison of the discrimination of high-sensitivity cardiac troponin I concentration at presentation in isolation (black) and in combination with 
a relative change in concentration (red), or in combination with an absolute change in concentration (blue) to distinguish type 1 myocardial 
infarction from other causes of myocardial injury or infarction in patients with a troponin value above the sex-specific 99th percentile upper 
reference limit at presentation. Panel A compares relative and absolute thresholds of 15 ng/L and 20% respectively, and Panel B compares 
absolute and relative change on a continuous scale. 
 
 
 
